Triclosan derivatives: Towards potent inhibitors of drug-sensitive and drug-resistant Mycobacterium tuberculosis

Joel S. Freundlich, Feng Wang, Catherine Vilchèze, Gulcin Gulten, Robert Langley, Guy A. Schiehser, David P. Jacobus, William R. Jacobs, James C. Sacchettini

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

Triclosan has been previously shown to inhibit InhA, an essential enoyl acyl carrier protein reductase involved in mycolic acid biosynthesis, the inhibition of which leads to the lysis of Mycobacterium tuberculosis. Using a structure-based drug design approach, a series of 5-substituted triclosan derivatives was developed. Two groups of derivatives with alkyl and aryl substituents, respectively, were identified with dramatically enhanced potency against purified InhA. The most efficacious inhibitor displayed an IC 50 value of 21 nM, which was 50-fold more potent than triclosan. X-ray crystal structures of InhA in complex with four triclosan derivatives revealed the structural basis for the inhibitory activity. Six selected triclosan derivatives were tested against isoniazid-sensitive and resistant strains of M. tuberculosis. Among those, the best inhibitor had an MIC value of 4.7 μgmL -1 (13 μm), which represents a tenfold improvement over the bacteriocidal activity of triclosan. A subset of these triclosan analogues was more potent than isoniazid against two isoniazid-resistant M. tuberculosis strains, demonstrating the significant potential for structure-based design in the development of next generation antitubercular drugs.

Original languageEnglish (US)
Pages (from-to)241-248
Number of pages8
JournalChemMedChem
Volume4
Issue number2
DOIs
StatePublished - Feb 13 2009

Fingerprint

Triclosan
Multidrug-Resistant Tuberculosis
Mycobacterium tuberculosis
Derivatives
Pharmaceutical Preparations
Isoniazid
Mycolic Acids
Acyl Carrier Protein
Antitubercular Agents
Drug Design
Biosynthesis
Oxidoreductases
Crystal structure
X-Rays
X rays

Keywords

  • Antibiotics
  • Drug resistance
  • Fatty acids
  • Triclosan
  • Tuberculosis

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Organic Chemistry

Cite this

Freundlich, J. S., Wang, F., Vilchèze, C., Gulten, G., Langley, R., Schiehser, G. A., ... Sacchettini, J. C. (2009). Triclosan derivatives: Towards potent inhibitors of drug-sensitive and drug-resistant Mycobacterium tuberculosis. ChemMedChem, 4(2), 241-248. https://doi.org/10.1002/cmdc.200800261

Triclosan derivatives : Towards potent inhibitors of drug-sensitive and drug-resistant Mycobacterium tuberculosis. / Freundlich, Joel S.; Wang, Feng; Vilchèze, Catherine; Gulten, Gulcin; Langley, Robert; Schiehser, Guy A.; Jacobus, David P.; Jacobs, William R.; Sacchettini, James C.

In: ChemMedChem, Vol. 4, No. 2, 13.02.2009, p. 241-248.

Research output: Contribution to journalArticle

Freundlich, JS, Wang, F, Vilchèze, C, Gulten, G, Langley, R, Schiehser, GA, Jacobus, DP, Jacobs, WR & Sacchettini, JC 2009, 'Triclosan derivatives: Towards potent inhibitors of drug-sensitive and drug-resistant Mycobacterium tuberculosis', ChemMedChem, vol. 4, no. 2, pp. 241-248. https://doi.org/10.1002/cmdc.200800261
Freundlich, Joel S. ; Wang, Feng ; Vilchèze, Catherine ; Gulten, Gulcin ; Langley, Robert ; Schiehser, Guy A. ; Jacobus, David P. ; Jacobs, William R. ; Sacchettini, James C. / Triclosan derivatives : Towards potent inhibitors of drug-sensitive and drug-resistant Mycobacterium tuberculosis. In: ChemMedChem. 2009 ; Vol. 4, No. 2. pp. 241-248.
@article{27ac6cab99994e0080872e95f237321b,
title = "Triclosan derivatives: Towards potent inhibitors of drug-sensitive and drug-resistant Mycobacterium tuberculosis",
abstract = "Triclosan has been previously shown to inhibit InhA, an essential enoyl acyl carrier protein reductase involved in mycolic acid biosynthesis, the inhibition of which leads to the lysis of Mycobacterium tuberculosis. Using a structure-based drug design approach, a series of 5-substituted triclosan derivatives was developed. Two groups of derivatives with alkyl and aryl substituents, respectively, were identified with dramatically enhanced potency against purified InhA. The most efficacious inhibitor displayed an IC 50 value of 21 nM, which was 50-fold more potent than triclosan. X-ray crystal structures of InhA in complex with four triclosan derivatives revealed the structural basis for the inhibitory activity. Six selected triclosan derivatives were tested against isoniazid-sensitive and resistant strains of M. tuberculosis. Among those, the best inhibitor had an MIC value of 4.7 μgmL -1 (13 μm), which represents a tenfold improvement over the bacteriocidal activity of triclosan. A subset of these triclosan analogues was more potent than isoniazid against two isoniazid-resistant M. tuberculosis strains, demonstrating the significant potential for structure-based design in the development of next generation antitubercular drugs.",
keywords = "Antibiotics, Drug resistance, Fatty acids, Triclosan, Tuberculosis",
author = "Freundlich, {Joel S.} and Feng Wang and Catherine Vilch{\`e}ze and Gulcin Gulten and Robert Langley and Schiehser, {Guy A.} and Jacobus, {David P.} and Jacobs, {William R.} and Sacchettini, {James C.}",
year = "2009",
month = "2",
day = "13",
doi = "10.1002/cmdc.200800261",
language = "English (US)",
volume = "4",
pages = "241--248",
journal = "ChemMedChem",
issn = "1860-7179",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Triclosan derivatives

T2 - Towards potent inhibitors of drug-sensitive and drug-resistant Mycobacterium tuberculosis

AU - Freundlich, Joel S.

AU - Wang, Feng

AU - Vilchèze, Catherine

AU - Gulten, Gulcin

AU - Langley, Robert

AU - Schiehser, Guy A.

AU - Jacobus, David P.

AU - Jacobs, William R.

AU - Sacchettini, James C.

PY - 2009/2/13

Y1 - 2009/2/13

N2 - Triclosan has been previously shown to inhibit InhA, an essential enoyl acyl carrier protein reductase involved in mycolic acid biosynthesis, the inhibition of which leads to the lysis of Mycobacterium tuberculosis. Using a structure-based drug design approach, a series of 5-substituted triclosan derivatives was developed. Two groups of derivatives with alkyl and aryl substituents, respectively, were identified with dramatically enhanced potency against purified InhA. The most efficacious inhibitor displayed an IC 50 value of 21 nM, which was 50-fold more potent than triclosan. X-ray crystal structures of InhA in complex with four triclosan derivatives revealed the structural basis for the inhibitory activity. Six selected triclosan derivatives were tested against isoniazid-sensitive and resistant strains of M. tuberculosis. Among those, the best inhibitor had an MIC value of 4.7 μgmL -1 (13 μm), which represents a tenfold improvement over the bacteriocidal activity of triclosan. A subset of these triclosan analogues was more potent than isoniazid against two isoniazid-resistant M. tuberculosis strains, demonstrating the significant potential for structure-based design in the development of next generation antitubercular drugs.

AB - Triclosan has been previously shown to inhibit InhA, an essential enoyl acyl carrier protein reductase involved in mycolic acid biosynthesis, the inhibition of which leads to the lysis of Mycobacterium tuberculosis. Using a structure-based drug design approach, a series of 5-substituted triclosan derivatives was developed. Two groups of derivatives with alkyl and aryl substituents, respectively, were identified with dramatically enhanced potency against purified InhA. The most efficacious inhibitor displayed an IC 50 value of 21 nM, which was 50-fold more potent than triclosan. X-ray crystal structures of InhA in complex with four triclosan derivatives revealed the structural basis for the inhibitory activity. Six selected triclosan derivatives were tested against isoniazid-sensitive and resistant strains of M. tuberculosis. Among those, the best inhibitor had an MIC value of 4.7 μgmL -1 (13 μm), which represents a tenfold improvement over the bacteriocidal activity of triclosan. A subset of these triclosan analogues was more potent than isoniazid against two isoniazid-resistant M. tuberculosis strains, demonstrating the significant potential for structure-based design in the development of next generation antitubercular drugs.

KW - Antibiotics

KW - Drug resistance

KW - Fatty acids

KW - Triclosan

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=60849124512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60849124512&partnerID=8YFLogxK

U2 - 10.1002/cmdc.200800261

DO - 10.1002/cmdc.200800261

M3 - Article

C2 - 19130456

AN - SCOPUS:60849124512

VL - 4

SP - 241

EP - 248

JO - ChemMedChem

JF - ChemMedChem

SN - 1860-7179

IS - 2

ER -